DEXLANSOPRAZOLE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H14F3N3O2S
Molecular Weight	369.361
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(C[S@@+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F

InChI

InChIKey=MJIHNNLFOKEZEW-RUZDIDTESA-N

InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H14F3N3O2S
Molecular Weight	369.361
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain healing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 30 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20974316	Inhibitor 8146

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erosive esophagitis 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	Primary		Approved 8307	DEXILANT Approved Use DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks. Launch Date 1.23327362E12
Heartburn 19 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	Curative		Approved 8307	DEXILANT Approved Use DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks. Launch Date 1.23327362E12

C_max

Value	Dose	Analyte	Population
1136 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00847210	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Adolescents sex: food status:
691 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00847210	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Adolescents sex: food status:
16.1 (ng/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
33.5 (ng/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
37.3 (ng/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
1005 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
559 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
964 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
658 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1397 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
143.2 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
55.5 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
87.6 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
2149 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
2628 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
3330 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
128 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
62 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
96 (ng*h/mL)/mg Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
1914 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
2892 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
3747 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01045096	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
3275 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
6529 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEXLANSOPRAZOLE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.59 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00847210	60 mg 1 times / day multiple, oral dose: 60 mg route of administration: oral experiment type: multiple co-administered:		DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Adolescents sex: food status:
1.66 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00847210	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: oral experiment type: multiple co-administered:		DEXLANSOPRAZOLE plasma	Homo sapiens population: unhealthy age: Adolescents sex: food status:

Doses

Dose	Population	Adverse events
30 mg 2 times / day multiple, intravenous Dose: 30 mg, 2 times / day Route: intravenous Route: multiple Dose: 30 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28138748	healthy, 18-29 years n = 18 Health Status: healthy Age Group: 18-29 years Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/28138748	Sources: https://pubmed.ncbi.nlm.nih.gov/28138748
90 mg single, intravenous Dose: 90 mg Route: intravenous Route: single Dose: 90 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28138748	healthy, 18-29 years n = 8 Health Status: healthy Age Group: 18-29 years Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28138748	Sources: https://pubmed.ncbi.nlm.nih.gov/28138748
300 mg single, oral Highest studied dose Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/19826060	healthy, 35 years (range: 18 - 50 years) n = 36 Health Status: healthy Age Group: 35 years (range: 18 - 50 years) Sex: M+F Population Size: 36 Sources: https://pubmed.ncbi.nlm.nih.gov/19826060	Sources: https://pubmed.ncbi.nlm.nih.gov/19826060
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	unhealthy, 48 years (range: 18-90 years) n = 2218 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 2218 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (0.7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 2218 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 2218 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	Disc. AE: Abdominal pain... AEs leading to discontinuation/dose reduction: Abdominal pain (0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 455 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 455 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	unhealthy, 48 years (range: 18-90 years) n = 1754 Health Status: unhealthy Age Group: 48 years (range: 18-90 years) Sex: M+F Population Size: 1754 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35	Disc. AE: Diarrhea, Abdominal pain... AEs leading to discontinuation/dose reduction: Diarrhea (0.7%) Abdominal pain (0.6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 35
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2311 Health Status: unhealthy Age Group: adult Population Size: 2311 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	Disc. AE: Dyspepsia, Eructation... AEs leading to discontinuation/dose reduction: Dyspepsia (3 patients) Eructation (2 patients) Nausea (6 patients) Vomiting (6 patients) Erosive esophagitis (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
90 mg 1 times / day steady, oral Dose: 90 mg, 1 times / day Route: oral Route: steady Dose: 90 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	unhealthy, adult n = 2142 Health Status: unhealthy Age Group: adult Population Size: 2142 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36	Disc. AE: Dyspepsia, Eructation... AEs leading to discontinuation/dose reduction: Dyspepsia (1 patient) Eructation (1 patient) Nausea (9 patients) Vomiting (6 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf Page: p. 36
60 mg 2 times / day steady, oral Overdose Dose: 60 mg, 2 times / day Route: oral Route: steady Dose: 60 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	Other AEs: Hypertension... Other AEs: Hypertension (serious) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670 inhibitor 1532	inhibitor 1695	inhibitor 1789

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A1 104 CYP1A2 1463 CYP2A6 670 CYP2B6 770 CYP2C8 869 CYP2E1 846 CYP2C19 1410	CYP2C19 955

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A1 206	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=11 Page: 11.0	unlikely
CYP2A6 702	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=13 Page: 11.0	unlikely
CYP2B6 946	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=14 Page: 11.0	unlikely
CYP2C8 923	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=15 Page: 11.0	unlikely
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=17 Page: 11.0	unlikely
CYP2E1 929	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=18 Page: 11.0	unlikely
CYP3A4 1857	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=19 Page: 11.0	unlikely
CYP1A2 1620	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=12 Page: 11.0	unlikely	no (co-administration study) Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered theophylline (CYP1A2 substrate) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=12 Page: 11.0
CYP2C9 1747	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=16 Page: 11.0	unlikely	no (co-administration study) Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered phenytoin (CYP2C9 substrate) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=16 Page: 11.0
CYP2C19 1484	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=19#page=12; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930293/#:~:text=Metabolism,and%2048%25%20in%20the%20feces.&text=No%20dose%20adjustments%20are%20needed,impairment%20or%20mild%20hepatic%20impairment.	weak	unknown (co-administration study) Comment: The mean AUC of the active metabolite of clopidogrel was reduced by approximately 9% (mean AUC ratio was 91%, with 90% CI of 86- 97%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=19#page=12; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930293/#:~:text=Metabolism,and%2048%25%20in%20the%20feces.&text=No%20dose%20adjustments%20are%20needed,impairment%20or%20mild%20hepatic%20impairment.

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=10 Page: 10.0	yes
CYP2C19 955	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=10 Page: 10,12	yes		yes (pharmacogenomic study) Comment: mean dexlansoprazole Cmax and AUC values were up to 2 times higher in intermediate compared to extensive metabolizers; in poor metabolizers, mean Cmax was up to 4 times higher and mean AUC was up to 12 times higher compared to extensive metabolizers Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022287s019lbl.pdf#page=10 Page: 10,12

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY521004	https://www.001chemical.com/chem/138530-94-6
AEchem Scientific Corp., USA	AE047759	http://www.aechemsc.com/info_products/AE047759.php
AK Scientific, Inc. (AKSCI)	W0028	http://www.aksci.com/item_detail.php?cat=W0028
AbMole Bioscience	M2627	http://www.abmole.com/products/dexlansoprazole.html
Aceschem	ACF021692	https://www.aceschem.com/catalog/138530-94-6.html
Achemo Scientific Limited	AC-74368	http://www.achemo.com/search/?Keyword= 138530-94-6
Acorn PharmaTech	ACN-046381	http://www.acornpharmatech.com/
Alsachim	890	http://www.alsachim.com/product-C1208-glo.bal-view.html
Ambinter	Amb2444038	http://www.ambinter.com/reference/2444038
Ark Pharm	AK170558	http://www.arkpharminc.com/products/138530-94-6.html
Aurum Pharmatech LLC	Q-1374	http://www.Aurumpharmatech.com/Product/ProductDetails/Q_1374
Chem Scene	CS-2820	http://www.chemscene.com/138530-94-6.html
ChemMol	49420692	http://www.chemmol.com/chemmol/49420692.html
ChemMol	99043051	http://www.chemmol.com/chemmol/99043051.html
Chemenu	CM106762	http://www.chemenu.com/products/CM106762
Chemspace	CSSB00016993951	https://chem-space.com/CSSB00016993951
Combi-Blocks	QC-7636	http://www.combi-blocks.com/cgi-bin/find.cgi?QC-7636
DC Chemicals	DC9092	http://www.dcchemicals.com/product_show-_R_Lansoprazole.html
Hairui	HR111133	http://www.hairuichem.com/en/product/138530-94-6.html
Lab Network	LN01349254	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01349254
MedChem Express	HY-13662B	https://www.medchemexpress.com/_R_-Lansoprazole.html
Molcore	MC521004	https://www.molcore.com/product/138530-94-6
Smolecule	S525777	http://www.smolecule.com/products/s525777
Synblock Inc	PB33188	http://www.synblock.com/product/138530-94-6.html
THE BioTek	bt-267370	https://www.thebiotek.com/product/inhibitors/bt-267370
abcr GmbH	AB455993	http://www.abcr.com/shop/en/AB455993
eNovation Chemicals	D588547	https://www.enovationchem.com/ProductDetails.asp?ProductID=D588547
eNovation Chemicals	D676423	https://www.enovationchem.com/ProductDetails.asp?ProductID=D676423
eNovation Chemicals	D762688	https://www.enovationchem.com/ProductDetails.asp?ProductID=D762688
iChemical	EBD14854	http://www.ichemical.com/products/138530-94-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.	2002 Jul	12152007
Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.	2005 Feb	15537834
Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.	2005 Jan	15788366
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.	2005 Jun	15856433
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.	2005 May	16012079
Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.	2006 Dec	17190370
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.	2006 Jan	16507515
Enantioselective disposition of lansoprazole and rabeprazole in human plasma.	2006 Jun	16755125
Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.	2008 May	18224311
Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.	2009	21694835
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.	2009	19515014
New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.	2009 Dec	20167000

Patents

Sample Use Guides

In Vivo Use Guide

For erosive esophagitis: One 60 mg capsule once daily for up to 8 weeks Relief of Heartburn: One 30 mg capsule once daily

Route of Administration: Oral

In Vitro Use Guide

A stably transfected gene reporter cell line AZ-AHR, derived from human hepatoma HepG2 cells transfected with a construct containing several AhR binding sites upstream of a luciferase reporter gene, was used for assessment of AhR transcriptional activity. Cells were incubated for 24 h with DEXLANSOPRAZOLE and/or vehicle (DMSO; 0.1% v/v), in the presence or absence of TCDD (10 nM; AZ-AHR cells) or DEX (100 nM; AZ-GR cells). After the treatments, cells were lysed and luciferase activity was measured. In parallel, cell viability was determined by conventional MTT test.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 20:36:17 UTC 2022` Edited by `admin` on `Fri Dec 16 20:36:17 UTC 2022`
Record UNII	UYE4T5I70X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEXLANSOPRAZOLE

Official Name

English

TAK-390

Code

English

1H-BENZIMIDAZOLE, 2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-

Systematic Name

English

DEXILANT

Brand Name

English

NSC-758710

Code

English

T-168390

Code

English

dexlansoprazole [INN]

Common Name

English

LANSOPRAZOLE, (R)-

Common Name

English

DEXLANSOPRAZOLE [VANDF]

Common Name

English

DEXILANT SOLUTAB

Brand Name

English

Dexlansoprazole [WHO-DD]

Common Name

English

KAPIDEX

Brand Name

English

2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE

Systematic Name

English

DEXLANSOPRAZOLE [MART.]

Common Name

English

LANSOPRAZOLE R-FORM

Common Name

English

LANSOPRAZOLE R-FORM [MI]

Common Name

English

(+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE

Systematic Name

English

DEXLANSOPRAZOLE [USAN]

Common Name

English

(R)-LANSOPRAZOLE

Common Name

English

DEXLANSOPRAZOLE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000000147